Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 19Smoldering Multiple Myeloma 1Recurrence 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm, Residual 1Natural Killer/T-cell Lymphoma 1Hematologic Neoplasms 1

Interventions

pembrolizumab 36Bevacizumab 25Cyclophosphamide 22Blood Specimen Collection 18Nivolumab 17Carboplatin 15Standard of Care 14Paclitaxel 14atezolizumab 13Gemcitabine 13Exercise 13Pemetrexed 11Fluorouracil 11Doxorubicin 11Cisplatin 11Cetuximab 10Radiotherapy 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Docetaxel 9durvalumab 8abemaciclib 8Temozolomide 8Surveys and Questionnaires 8Rituximab 8Prednisone 8Biopsy 8130-nm albumin-bound paclitaxel 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × isatuximab × 90 days × Clear all
NCT05145400 2026-06-02

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
50 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡